These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. Manesh A; John AO; Mathew B; Varghese L; Rupa V; Zachariah A; Varghese GM Mycoses; 2016 Dec; 59(12):765-772. PubMed ID: 27443253 [TBL] [Abstract][Full Text] [Related]
3. Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: a prospective cohort study. Manesh A; Devasagayam E; Bhanuprasad K; Varghese L; Kurien R; Cherian LM; Dayanand D; George MM; Kumar SS; Karthik R; Vanjare H; Peter J; Michael JS; Thomas M; Mathew BS; Samuel P; Peerawaranun P; Mukaka M; Rupa V; Varghese GM Clin Microbiol Infect; 2023 Oct; 29(10):1298-1305. PubMed ID: 37348653 [TBL] [Abstract][Full Text] [Related]
4. COVID-19-associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis. Bhattacharyya A; Sarma P; Kaur H; Kumar S; Bhattacharyya J; Prajapat M; Prakash A; Sharma S; Reddy DH; Thota P; Bansal S; Gautam BS; Medhi B Indian J Pharmacol; 2021; 53(6):499-510. PubMed ID: 34975140 [TBL] [Abstract][Full Text] [Related]
8. Post-COVID-19 rhino-orbito-cerebral mucormycosis-A clinico-mycological study from North India. Taneja J; Chatterjee K; Sasidharan J; Abbas SZ; Rai AK; Raychaudhury S; Das B; Das A Med Mycol; 2023 Jul; 61(7):. PubMed ID: 37442616 [TBL] [Abstract][Full Text] [Related]
9. Surgical & medical management of ROCM (Rhino-orbito-cerebral mucormycosis) epidemic in COVID-19 era and its outcomes - a tertiary care center experience. Soni K; Das A; Sharma V; Goyal A; Choudhury B; Chugh A; Kumar D; Yadav T; Jain V; Agarwal A; Garg M; Bhatnagar K; Elhence P; Bhatia PK; Garg MK; Misra S J Mycol Med; 2022 May; 32(2):101238. PubMed ID: 34979299 [TBL] [Abstract][Full Text] [Related]
10. A case report on clinical features, diagnosis, and treatment of rhino-orbito-cerebral mucormycosis. Ding JQ; Xie Y Immun Inflamm Dis; 2023 Nov; 11(11):e1080. PubMed ID: 38018593 [TBL] [Abstract][Full Text] [Related]
11. Spectrum of intracranial complications of rhino-orbito-cerebral mucormycosis - resurgence in the era of COVID-19 pandemic: a pictorial essay. Kaushik KS; Ananthasivan R; Acharya UV; Rawat S; Patil UD; Shankar B; Jose A Emerg Radiol; 2021 Dec; 28(6):1097-1106. PubMed ID: 34605991 [TBL] [Abstract][Full Text] [Related]
12. Corneal manifestations and treatment among patients with COVID-19-associated rhino-orbito-cerebral mucormycosis. Yadav R; Madan S; Rohatgi J; Sahu PK; Das S; Tandon A; Rai P; Verma P; Singh J; Bajaj I Indian J Ophthalmol; 2023 Jan; 71(1):101-108. PubMed ID: 36588217 [TBL] [Abstract][Full Text] [Related]
13. Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience. Ramamurthy LB; Bhandari R; Kanakpur S; Thejaswini P Indian J Ophthalmol; 2022 Mar; 70(3):1019-1024. PubMed ID: 35225564 [TBL] [Abstract][Full Text] [Related]
14. Rhino-orbito-cerebral mucormycosis during the COVID-19 third wave in 2021: an Egyptian preliminary report from a single tertiary hospital. Alloush TK; Mansour O; Alloush AT; Roushdy T; Hamid E; El-Shamy M; Shokri HM Neurol Sci; 2022 Feb; 43(2):799-809. PubMed ID: 34787754 [TBL] [Abstract][Full Text] [Related]
15. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India. Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032 [TBL] [Abstract][Full Text] [Related]
16. Rhino-orbito-cerebral mucormycosis. Raymundo IT; Araújo BG; Costa Cde C; Tavares JP; Lima CG; Nascimento LA Braz J Otorhinolaryngol; 2009; 75(4):619. PubMed ID: 19784435 [No Abstract] [Full Text] [Related]
17. The ROC Staging System for COVID-related Rhino-Orbital-Cerebral Mucormycosis. Naik MN; Rath S Semin Ophthalmol; 2022 Apr; 37(3):279-283. PubMed ID: 34260342 [TBL] [Abstract][Full Text] [Related]
18. Uncontrolled diabetes mellitus exacerbated by COVID-19-induced inflammation is the risk factor for COVID-19-associated rhino-orbito-cerebral mucormycosis: A matched pair case-control study. Karat S; Lobo AC; Satish D; Devaraj R; Manjooran RR; Nithyanandam S Indian J Ophthalmol; 2022 Aug; 70(8):3096-3101. PubMed ID: 35918980 [TBL] [Abstract][Full Text] [Related]
19. Refractory rhino-orbito-cerebral mucormycosis treated with intraconal amphotericin B. Guimarães JA; Moura FC Arq Bras Oftalmol; 2022; 85(1):77-81. PubMed ID: 34468552 [TBL] [Abstract][Full Text] [Related]